Collegium Pharmaceutical(US:COLL)2026-02-26 14:02Financial Data and Key Metrics Changes - In 2025, the company achieved record net revenues of $780.6 million, representing a 24% year-over-year increase, and adjusted EBITDA of $460.5 million, up 15% year-over-year [25][31] - The company generated over $329 million in cash from operations in 2025 and ended the year with over $386 million in cash, an increase of approximately $224 million from the end of 2024 [7][31] - GAAP net income for the quarter was $17 million, up 36% year-over-year, while full-year GAAP net income was $62.9 million, down 9% year-over-year due to a one-time loss on extinguishment of debt [29][30] Business Line Data and Key Metrics Changes - Jornay PM net revenue was $45.9 million in Q4, up 57% year-over-year, and $148.9 million for the full year, up 48% compared to pro forma 2024 revenue [26][31] - The pain portfolio generated $631.7 million in 2025, up 6% year-over-year, with all three core pain medicines delivering full-year growth [7][21] - Belbuca net revenue was $59.1 million in Q4, up 7% year-over-year, and $221.7 million in 2025, up 5% year-over-year [26][27] Market Data and Key Metrics Changes - Jornay's market share of the long-acting branded methylphenidate market grew to nearly 26% in Q4, up 6.5 percentage points year-over-year [18] - The pediatric and adolescent segment, which represents about 80% of total prescriptions, grew 14% year-over-year, while the adult segment grew 24% year-over-year [18][19] - The prescriber base for Jornay PM reached an all-time high of over 29,000 in Q4, up 21% year-over-year [18] Company Strategy and Development Direction - The company focuses on three strategic priorities: driving growth for Jornay PM, maximizing the durability of the pain portfolio, and strategically deploying capital to enhance shareholder value [4][10] - The company aims to expand its portfolio through business development while maintaining a strong balance sheet, as evidenced by the closing of a $980 million syndicated credit facility [8][34] - The company is committed to maximizing the life cycle of its pain portfolio and ensuring accessibility to its medicines [9][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive growth in 2026, expecting Jornay revenue to be in the range of $190 million-$200 million, representing over 30% annual growth [11][32] - The company anticipates a modest quarter-over-quarter decline in revenues in Q1 2026 due to typical seasonal dynamics, but remains optimistic about long-term growth [32][33] - Management highlighted the importance of ongoing investments in sales and marketing to support future growth, particularly for Jornay PM [10][11] Other Important Information - The company published its 2025 ESG report, emphasizing its commitment to social responsibility alongside financial performance [5][6] - The company repurchased $25 million in shares through its share repurchase program, reinforcing its capital deployment strategy [8][34] Q&A Session Questions and Answers Question: What assumptions underlie 2026 Jornay guidance, and how should we think about factors that could lead to upside? - Management indicated that growth is expected to be driven by demand growth, with relative stability in gross to nets between 2025 and 2026 [40] Question: Have there been any competitive developments in the ADHD market that could potentially impact Jornay demand? - Management noted that there have not been any material changes in competitive dynamics that could impact Jornay demand, emphasizing its differentiated delivery technology [41] Question: Can you help us frame how you're thinking about the ramp to peak for Jornay? - Management stated that they have not previously discussed peak sales but expect to see the impact of expanded sales and marketing efforts throughout 2026 [45] Question: How promotionally sensitive are Belbuca and Xtampza at this stage of their life cycle? - Management indicated that Belbuca and Xtampza are promotionally sensitive, and the sales team is focused on navigating the complex payer environment [47] Question: How are you thinking about acquiring a rare disease-focused asset? - Management expressed interest in rare disease assets but emphasized a preference for commercial or near-commercial assets that align with existing therapeutic areas [51][54]